A randomized study of epirubicin monotherapy every four or every two weeks in advanced breast cancer. A Hellenic Cooperative Oncology Group Study

Annals of Oncology

Volumn 8, Issue 12, 1997, Pages 1213-1220

  Fountzilas, G ^a   Athanassiades, A ^a   Giannakakis, T ^b   Briasoulis, E ^c   Bafaloukos, D ^d   Kalogera Fountzila, A ^a   Onienaoum, A ^e   Kalofonos, H ^e   Pectasides, D ^d   Andreopoulou, E ^c   Bamia, C ^f   Kosmidis, P ^d   Pavlidis, N ^c   Skarlos, D ^b  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b AGII ANARGIRI CANCER HOSPITAL   (Greece)

^c UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^d METAXA CANCER HOSPITAL   (Greece)

^e UNIVERSITY HOSPITAL OF PATRAS   (Greece)

^f Hellenic Cooperative Oncology Group   (Greece)

Author keywords

Breast neoplasms; Chemotherapy; Epirubicin

Indexed keywords

EPIRUBICIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG RESPONSE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL;

ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; EPIRUBICIN; FEMALE; HUMANS; MIDDLE AGED; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 7144260415     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008270307264     Document Type: Article

References (43)

1. Gersosimo R, Hong WK. Epirubicin: A review of the pharmacology, clinical activity and adverse effects of an adriamycin analogue. J Clin Oncol 1986; 4: 425-39.
2. Bonadonna G, Gianni L, Santoro A et al. Drugs ten years later: Epirubicin. Ann Oncol 1993; 4: 359-69.
3. McGown AT, Ward TH, Fox BW. Comparative studies of the uptake of daunorubicin in sensitive and resistant P388 cell lines by flow cytometry and biochemical extraction procedures. Cancer Chemother Pharmacol 1983; 11: 113-6.
4. Gurney H, Dodwell D, Thatcher N et al. Escalating drug delivery in cancer chemotherapy: A review of concepts and practice - part 1. Ann Oncol 1993; 4: 23-34.
5. Giulani FC, Coirin AK, Rice MR et al. Effect of 4-doxorubicin analogs on heterotransplantation of human tumors in congenitally athymic mice. Cancer Treat Rep 1981; 65: 1063-75.
6. Fountzilas G, Inone S, Ohnuma T et al. Schedule-dependent interaction of cytarabine plus doxorubicin or cytarabine plus minoxantrone in acute myelogenic leukemia cells in culture. Leukemia 1990; 4: 321-4.
7. Bonadonna G, Valagussa P. Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med 1981; 304: 10-5.
8. Hryniuk W, Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 1984; 2:1281-8.
9. Redmond C, Fisher B, Wieland HS et al. The methodologic dilemma in retrospectively correlating the amount of chemotherapy received in adjuvant therapy protocols with disease-free survival. Cancer Treat Rep 1983; 67: 519-26.
10. Henderson IC, Hayes DF, Gelman R. Dose-response in the treatment of breast cancer. Semin Oncol 1992; 19: 317-32.
11. Sledge GW, Antman KH. Progress in chemotherapy for metastatic breast cancer. Semin Oncol 1992; 19: 317-32.
12. Brambilla C, Rossi A, Bonfante V et al. Phase II study of doxorubicin versus epirubicin in advanced breast cancer. Cancer Treat Rep 1986; 70: 261-6.
13. Habeshaw T, Paul J, Jones R et al. Epirubicin at two dose levels with prednisolone as treatment for advanced breast cancer: The results of a randomized trial. J Clin Oncol 1991; 9: 295-304.
14. Fountzilas G, Skarlos D, Pavlidis N et al. High-dose epirubicin as a single agent in the treatment of patients with advanced breast cancer. Tumori 1991; 77: 232-6.
15. Fountzilas G, Skarlos D, Giannakakis T et al. Intensive chemotherapy with high-dose epirubicin every two weeks and prophylactic administration of Filgastrim in advanced breast cancer. Eur J Cancer 1994; 30A: 965-9.
16. Fountzilas G, Skarlos D, Katsohis C et al. High-dose epirubicin and r-met-hu G-CSF (Filgrastrim) in the treatment of patients with advanced breast cancer. A Hellenic Cooperative Oncology Group Study. Med Pediatr Oncol 1995; 24: 23-8.
17. Cavalli F, Beer M, Martz G et al. Concurrent or sequential use of cytotoxic chemotherapy and hormone treatment in advanced breast cancer: Report of the Swiss Group for Clinical Cancer Research. BMJ 1983; 286: 5-8.
18. Oken MM, Greech RH, Tormey DC et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-55.
19. Miller AB, Hoogsraten B, Staquet M et al. Reporting results of cancer treatment. Cancer 1981; 47: 207-14.
20. Woolson, RF. Statistical Methods for the Analysis of Biomedical Data. New York: John Wiley and Sons 1987.
21. Hosmer DW, Lemeshow S. Applied Logistic Regression. New York: John Wiley and Sons 1989.
22. Kaplan EL, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-81.
23. Mantel M. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50: 163-70.
24. Cox DR. Regression models and life tables. J R Statist Soc 1972; 34 (Series B): 187-220.
25. Andersen PK. Testing goodness of fit of Cox's regression and life model. Biometrics 1982; 38: 67-77.
26. Dixon WJ, Brown MB, Engleman L. BMDP Statistical Software Manual. Los Angeles: University of California Press 1990.
27. Goldie JH, Coldman AJ. Quantitative model for multiple levels of drug resistance in clinical tumors. Cancer Treat Rep 1983; 67: 923-31.
28. Skipper HE. Dose intensity versus total dose of chemotherapy: An experimental basis. Important Adv Oncol 1990; 43-64.
29. Hortobagyi GN, Bodey GP, Buzdar AU et al. Evaluation of high-dose versus standard FAC chemotherapy for advanced breast cancer in protected environment units: A prospective randomized study. J Clin Oncol 1987; 5: 354-64.
30. The French Epirubicin Study Group. A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil and either doxorubicin or epirubicin. J Clin Oncol 1988; 6: 679-88.
31. Italian Multicentre Breast Study with Epirubicin. Phase III randomized study of fluorouracil, epirubicin and cyclophosphamide vs. fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer: An Italian multicentre trial. J Clin Oncol 1988; 6: 976-82.
32. Focan C, Andrien JM, Closon MT et al. Dose-response relation of epirubicin-based first-line chemotherapy for advanced breast cancer: A prospective randomized trial. J Clin Oncol 1993; 11: 1253-63.
33. French Epirubicin Study Group. A prospective randomized trial comparing epirubicin monochemotherapy to two fluorouracil, cyclophosphamide, and epirubicin regimens differing in epirubicin dose in advanced breast cancer patients. J Clin Oncol 1991; 9: 305-12.
34. Marschner N, Kreienberg R, Souchon R et al. Evaluation of the importance and relevance of dose intensity using epirubicin and cyclophosphamide in metastatic breast cancer: Interim analysis of a prospective randomized trial. Semin Oncol 1994; 21 (Suppl 1): 10-6.
35. Bastholt L, Dalmark M, Gjedde SB et al. Dose- response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: A randomized study of epirubicin at four different dose levels performed by the Danish Breast Cancer Cooperative Group. J Clin Oncol 1996; 14: 1146-55.
36. Ebbs SR, Saunders JA. Graham H et al. A randomized trial of epidoxorubicin at two different dosages and two administration systems. Acta Oncol 1989; 28: 887-92.
37. Bezwoda WR, Dansey R, Seymour L. High-dose 4'-epiadriamycin for treatment of breast cancer refractory to standard dose anthracycline chemotherapy: Achievement of second responses. Oncology 1990; 47: 4-8.
38. Ferguson JE, Dodwell DJ, Seymour AM et al. High-dose, dose-intensive chemotherapy with doxorubicin and cyclophosphamide for the treatment of advanced breast cancer. Br J Cancer 1993; 67: 825-9.
39. Blomqvist C, Elomaa I, Rissanen P et al. Influence of treatment schedule on toxicity and efficacy of cyclophosphamide, epirubicin and fluorouracil in metastatic breast cancer: A randomized trial comparing weekly and every-4-week administration. J Clin Oncol 1993; 11: 467-73.
40. Canellos GP, Pocock SJ, Taylor SG et al. Combination chemotherapy for metastatic breast carcinoma. Cancer 1976; 38: 1882-6.
41. Carmo-Pereira J, Costa FO, Miles DW et al. High-dose epirubicin as primary chemotherapy in advanced breast cancer carcinoma: A phase II study. Cancer Chemother Pharmacol 1991; 27: 394-6.
42. A'Hern RP, Ebbs SR, Baum MB. Does chemotherapy improve survival in advanced breast cancer? A statistical overview. Br J Cancer 1988; 57: 615-8.
43. Norton L, Simon R. The Norton-Simon hypothesis revisited. Cancer Treat Rep 1986; 70: 163-9.